Authors
Latest:
Data Quality Issues Plague the US Health Care SystemOleg Bess, MD, explains why data quality is essential to improving the United States health care system.
Latest:
Dr. Jain on Ongoing Research Efforts in MCLPreetesh Jain, MD, PhD, discusses ongoing research efforts in mantle cell lymphoma.
Latest:
Dr. Doroshow on the Impact of the COVID-19 Pandemic on Cancer CareDeborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.
Latest:
Ongoing Clinical Trials With ADC Therapy in HR+ Metastatic Breast CancerBreast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.
Latest:
Treatment Options in Early Relapse Multiple MyelomaDr Joseph Mikhael and expert panel review current treatment options for patients with early relapse multiple myeloma, in accordance with current NCCN guidelines.
Latest:
Dr. Shah on the Significance of the Approval of Sodium Thiosulfate in Pediatric Solid TumorsNilay Shah, MD, discusses the significance of the approval of sodium thiosulfate for pediatric patients with cisplatin-treated pediatric solid tumors.
Latest:
Long-Term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-Positive Thyroid CarcinomaDr. Waguespack reviews efficacy and safety data for larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Latest:
Future Directions for HCC ManagementDrs Josep Llovet, Stephen L. Chan, and Andrea Casadei Gardini discuss the future treatment landscape for HCC.
Latest:
Dr. Kato on the Characterization of BRAF Mutations in OncologyShumei Kato, MD, discusses the characterization of BRAF mutations in oncology.
Latest:
Dr. Arora on the Evolution of Treatment in Follicular LymphomaMadan L. Arora, MD, discusses the evolution of treatment in follicular lymphoma.
Latest:
Dr. Lipson on the Impact of Preoperative Nivolumab Plus Relatlimab in NSCLCEvan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).
Latest:
Dr. Azzi on the Utilization of the Signatera ctDNA Assay in the CIRCULATE-US Trial in CRCGeorges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.
Latest:
Dr. Talwar on the Utility of Immunotherapy in Metastatic Urothelial CarcinomaVineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.
Latest:
Dr. Akbar on the Efficacy of Monoclonal Antibodies Across Various Trials in R/R ALLUsman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Latest:
Dr. Cheah on the Investigation of BGB-11417 With or Without Zanubrutinib in CLLChan Cheah, MBBS, discusses the investigation of BGB-11417 with or without zanubrutinib in chronic lymphocytic leukemia.
Latest:
Operational Processes and ChallengesMark Robson, MD; John Henson, MD; Ashley Ross, MD, PhD; and Dana Farengo Clark, MS, LCGC, discuss operational processes and techniques for counseling patients about germline testing.
Latest:
Dr. Brayer on the Promise of BiTEs in Multiple MyelomaJason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.
Latest:
Dr. Ramaswamy on Capecitabine and Irinotecan Monotherapy in Gallbladder CancerAnant Ramaswamy, MD, discusses a phase 2 multicenter clinical trial evaluating the efficacy of capecitabine plus irinotecan versus irinotecan monotherapy in advanced gallbladder cancer.
Latest:
Institutional Perspectives in Cancer- GI: Chaired by Anne M Noonan, MBBChInstitutional Perspectives in Cancer- GI: Chaired by Anne M Noonan, MBBCh
Latest:
Dr. Zarrabi on the Real-World Data With Axitinib/Pembrolizumab Vs Ipilimumab/Nivolumab in Clear Cell RCCKevin Zarrabi, MD, discusses an analysis of real-world outcomes with axitinib plus pembrolizumab vs ipilimumab plus nivolumab in patients with metastatic clear cell renal cell carcinoma.
Latest:
Dr. Dent on the Clinical Implications of the MONALEESA-2 Trial in HR+/HER2- Breast CancerSusan Faye Dent, MD, discusses the clinical implications of the phase 3 MONALEESA-2 trial in hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast CancerMartine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.
Latest:
Advanced Biliary Tract Cancers: Novel Biomarker StrategiesClosing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Latest:
Dr. Hays on the Importance of Clinical Trials in CRCJohn L. Hays, MD, PhD, discusses the importance of clinical trials in colorectal cancer.
Latest:
Creating the In-Person Experience on a Virtual PlatformThe coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.
Latest:
Dr. Rajdev on Detecting HER2 Positivity in GI CancerLakshmi Rajdev, MD, MS, discusses detecting HER2 positivity in patients with gastrointestinal cancers.
Latest:
Direct Partnership With Patients May Accelerate Cancer Research and Precision OncologyDuring the past several decades, cancer research has produced revolutionary discoveries leading to dramatic results for many patients.
Latest:
Dr. Ramnaraign on the Evaluation of Atezolizumab Plus Tivozanib in GI MalignanciesBrian Ramnaraign, MD, discusses the evaluation of atezolizumab plus tivozanib in a phase 1b/2 trial in patients with pancreatic, gallbladder, and bile duct cancers.
Latest:
Dr. Nichols on the Prognosis of Patients With VHL DiseaseKim E. Nichols, MD, discusses the prognosis of patients with von Hippel-Lindau disease.
